Bioxcel Therapeutics Logo
Previous slide
Next slide

Our AI-based approach is designed to:

  • Enhance R&D efficiencies
  • Shorten development timelines
  • Increase probability of success

Latest News

VIEW ALL NEWS
Jul 16, 2024
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual FilmVIEW RELEASE
Jun 25, 2024
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
May 28, 2024
BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceVIEW RELEASE
VIEW ALL NEWS

Stock Information

BioXcel Therapeutics, Inc.

Jul 26, 2024 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

1.15

CHANGE

-0.02 (-1.71%)
EVENTS
SIGN UP FOR EMAIL ALERTS
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2024 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

All other trademarks are the properties of their respective owners.
Copyright © 2023 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.